Patents by Inventor Berge A. Minassian

Berge A. Minassian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNAI THERAPY FOR APBD AND LAFORA DISEASE
    Publication number: 20250011791
    Abstract: The present disclosure provides methods and compositions for the treatment of glycogen storage disorders, such as, for example, Lafora Disease and adult polyglucosan body disease. The methods and compositions of the present disclosure comprise isolated nucleic acid molecules, rAAV vectors and rAAV viral vectors comprising polynucleotide sequences encoding for artificial micro RNAs (amiRNAs) directed against GYS1.
    Type: Application
    Filed: November 17, 2022
    Publication date: January 9, 2025
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Berge A. MINASSIAN, Emrah GUMUSGOZ, Mayank VERMA
  • TRANSGENE CASSETTES, AAV VECTORS, AND AAV VIRAL VECTORS FOR EXPRESSION OF HUMAN CODON-OPTIMIZED CSTB
    Publication number: 20240344084
    Abstract: The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to CSTB loss and/or misfunction. The methods and compositions of the present disclosure include rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules encoding CSTB polypeptides.
    Type: Application
    Filed: March 13, 2024
    Publication date: October 17, 2024
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Berge A. MINASSIAN, Emrah GUMUSGOZ
  • GENE THERAPY FOR ANGELMAN SYNDROME
    Publication number: 20240318198
    Abstract: The present disclosure provides methods and compositions for the treatment of Angelman Syndrome The methods and compositions of the present disclosure comprise isolated nucleic acid molecules, rAAV vectors and rAAV viral vectors comprising polynucleotide sequences encoding for short hairpin RNA (shRNA) molecules directed against UBE3A-ATS.
    Type: Application
    Filed: February 2, 2022
    Publication date: September 26, 2024
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Ryan BUTLER, Steven J. GRAY, Hye Ri KANG, Berge A. MINASSIAN, Emrah GUMUSGOZ
  • Transgene cassettes, AAV vectors, and AAV viral vectors for expression of human codon-optimized CSTB
    Patent number: 11946065
    Abstract: The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to CSTB loss and/or misfunction. The methods and compositions of the present disclosure include rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules encoding CSTB polypeptides.
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: April 2, 2024
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Berge A. Minassian, Emrah Gumusgoz
  • TRANSGENE CASSETTES, AAV VECTORS, AND AAV VIRAL VECTORS FOR EXPRESSION OF HUMAN CODON-OPTIMIZED CSTB
    Publication number: 20220049270
    Abstract: The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to CSTB loss and/or misfunction. The methods and compositions of the present disclosure include rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules encoding CSTB polypeptides.
    Type: Application
    Filed: July 28, 2021
    Publication date: February 17, 2022
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Berge A. MINASSIAN, Emrah GUMUSGOZ
  • MECP2E1 GENE
    Publication number: 20200270693
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Application
    Filed: March 2, 2020
    Publication date: August 27, 2020
    Applicants: The Hospital for Sick Children, Centre for Addiction and Mental Health
    Inventors: Berge A. Minassian, John B. Vincent
  • MECP2E1 GENE
    Publication number: 20200270695
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Application
    Filed: March 2, 2020
    Publication date: August 27, 2020
    Applicants: The Hospital For Sick Children, Centre for Addiction and Mental Health
    Inventors: Berge A. Minassian, John B. Vincent
  • MECP2E1 gene
    Patent number: 10577657
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: March 3, 2020
    Assignees: The Hospital For Sick Children, Centre for Addiction and Mental Health
    Inventors: Berge A. Minassian, John B. Vincent
  • MECP2E1 gene
    Patent number: 10577658
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: March 3, 2020
    Assignees: The Hospital for Sick Children, Centre for Addiction and Mental Health
    Inventors: Berge A. Minassian, John B. Vincent
  • MECP2E1 GENE
    Publication number: 20180265926
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Application
    Filed: March 7, 2018
    Publication date: September 20, 2018
    Applicants: The Hospital For Sick Children, Centre for Addiction and Mental Health
    Inventors: Berge A. Minassian, John B. Vincent
  • MECP2E1 GENE
    Publication number: 20180265927
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Application
    Filed: March 7, 2018
    Publication date: September 20, 2018
    Applicants: The Hospital for Sick Children, Centre for Addiction and Mental Health
    Inventors: Berge A. Minassian, John B. Vincent
  • MECP2E1 GENE
    Publication number: 20170152564
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Application
    Filed: February 9, 2017
    Publication date: June 1, 2017
    Applicants: The Hospital for Sick Children, Centre for Addiction and Metal Health
    Inventors: Berge A. Minassian, John B. Vincent
  • MECP2E1 GENE
    Publication number: 20170137887
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Application
    Filed: January 31, 2017
    Publication date: May 18, 2017
    Applicants: The Hospital for Sick Children, Centre for Addiction and Mental Health
    Inventors: Berge A. Minassian, John B. Vincent
  • MECP2E1 gene
    Patent number: 9605314
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: March 28, 2017
    Assignees: The Hospital for Sick Children, Centre for Addiction and Mental Health
    Inventors: Berge A. Minassian, John B. Vincent
  • MECP2E1 gene
    Patent number: 9568484
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Grant
    Filed: November 18, 2008
    Date of Patent: February 14, 2017
    Assignees: Centre for Addiction and Mental Health, The Hospital for Sick Children
    Inventors: Berge A. Minassian, John B. Vincent
  • LaFORA'S DISEASE GENE
    Publication number: 20160215347
    Abstract: A novel gene (EPM2A) that is deleted or mutated in people with Lafora's disease is described. The EPM2A gene encodes a protein having an active catalytic site of a protein tyrosine phosphatase. Many different sequence mutations as well as several microdeletions in EPM2A have been found that co-segregate with Lafora's disease.
    Type: Application
    Filed: April 7, 2016
    Publication date: July 28, 2016
    Applicants: The Hospital for Sick Children, McGill University, U.S. Government Department of Veterans Affairs, The Regents of the University of California
    Inventors: Stephen W. Scherer, Berge A. Minassian, Antonio Delgado-Escueta, Guy Rouleau
  • LAFORA'S DISEASE GENE
    Publication number: 20160177393
    Abstract: A novel gene (EPM2B) that is mutated in humans and dogs with Lafora's disease is described.
    Type: Application
    Filed: December 17, 2015
    Publication date: June 23, 2016
    Applicant: THE HOSPITAL FOR SICK CHILDREN
    Inventors: Stephen W. Scherer, Berge A. Minassian
  • Lafora's disease gene
    Patent number: 9334539
    Abstract: A novel gene (EPM2A) that is deleted or mutated in people with Lafora's disease is described. The EPM2A gene encodes a protein having an active catalytic site of a protein tyrosine phosphatase. Many different sequence mutations as well as several microdeletions in EPM2A have been found that co-segregate with Lafora's disease.
    Type: Grant
    Filed: June 24, 2013
    Date of Patent: May 10, 2016
    Assignees: The Hospital for Sick Children, McGill University, The Regents of the University of California, U.S. Department of Veterans Affairs
    Inventors: Stephen W. Scherer, Berge A. Minassian, Antonio Delgado-Escueta, Guy Rouleau
  • Lafora's disease gene
    Patent number: 9222135
    Abstract: A novel gene (EPM2B) that is mutated in humans and dogs with Lafora's disease is described.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: December 29, 2015
    Assignee: The Hospital for Sick Children
    Inventors: Stephen W. Scherer, Berge A. Minassian
  • MECP2E1 GENE
    Publication number: 20140186834
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Application
    Filed: December 9, 2013
    Publication date: July 3, 2014
    Applicants: Centre for Addiction and Mental Health, The Hospital For Sick Children
    Inventors: Berge A. Minassian, John B. Vincent